Nocebo effects in multiple sclerosis trials: a meta-analysis
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To estimate the incidence and severity of nocebo responses in trials of symptomatic treatments (STs) and disease-modifying treatments (DMTs) for multiple sclerosis (MS). Methods: We conducted a systematic Medline search for all randomised, placebo-controlled MS trials published between 1989 and 2009. Meta-analysis of the incidence of nocebo responses was performed by pooling the percentage of placebo-treated patients that exhibited adverse events. Nocebo severity was calculated from the percentage of placebo-treated patients that dropped-out due to drug-related adverse events. Results: Data were extracted from 56 DMT and 44 ST eligible trials. The pooled incidence of nocebo responses was 74.4% (95% CI: 69.92—88.30) in DMT trials and 25.3% (95% CI: 15.24—36.90) in ST trials and was significantly higher in the former ( p < 0.0001). The pooled nocebo severity was 2.1% (95% CI: 1.6—2.67) in DMT and 2.34% (95% CI: 1.54—3.29) in ST trials. Meta-regression analysis revealed a higher nocebo incidence in parallel design ST studies compared to crossover ones ( p = 0.013) and a higher nocebo severity in phase II ST studies compared to phase III ones ( p = 0.0001). Nocebo severity in DMT trials exhibited an association with the year of study publication ( p = 0.011) and the frequency of drug administration ( p = 0.0082). Conclusions: Nocebo responses in MS trials are substantial and appear to have increased significantly in recent years with important implications for both trial design and clinical practice. Furthermore, nocebo responses exhibit an association with medication and trial-related factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Nonspecific medication side effects and the nocebo phenomenon
Barsky, A. J. (2002) · JAMA · doi:10.1001/jama.287.5.622 · Cited by 784 · cited 3×
“Nocebo effects have important implications for MS trial design and clinical practice.(7) Awareness of the phenomenon is a prerequisite for enabling clinical investigators and practitioners to better recognize nonspecific side effects.”
BackgroundMethodInfluentialWhen words are painful: unraveling the mechanisms of the nocebo effect
Benedetti, F., Lanotte, M., Lopiano, L., & Colloca, L. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.02.020 · Cited by 636
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect
Benedetti, F., Amanzio, M., Vighetti, S., & Asteggiano, G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2947-06.2006 · Cited by 419 · cited 1×
“Neuroimaging and pharmacological studies have provided insight into the physiological(18) and biochemical basis of the nocebo phenomenon.(19) From the patient characteristics examined in this study, only the relapsing–remitting course exhibited a negative association with the severity of nocebo responses seen in MS cl…”
BackgroundCannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up
Zajicek, J. P. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.070136 · Cited by 335
Modafinil for fatigue in MS: A randomized placebo-controlled double-blind study
Stankoff, B., Waubant, E., Confavreux, C., Edan, G., Debouverie, M., Rumbach, L., Moreau, T., Pelletier, J., Lubetzki, C., Clanet, M., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000158272.27070.6a · Cited by 318
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis
Ehde, D. M., Kraft, G. H., Chwastiak, L., Sullivan, M. D., Gibbons, L. E., Bombardier, C. H., & Wadhwani, R. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.08.002 · Cited by 107
Cited by
The placebo response in medicine: minimize, maximize or personalize?
Enck, P., Bingel, U., Schedlowski, M., & Rief, W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3923 · Cited by 671
Schedlowski, M., Enck, P., Rief, W., & Bingel, U. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.009423 · Cited by 323
“The side effects reported by placebo arms in multiple sclerosis treatments have been substantially higher when diseasemodifying drugs were investigated compared with trials investigating symptomatic treatments (Papadopoulos and Mitsikostas, 2010).”
BackgroundZis, P., Shafique, F., Hadjivassiliou, M., Blackburn, D., Venneri, A., Iliodromiti, S., Mitsikostas, D.-D., & Sarrigiannis, P. G. (2020) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12946 · Cited by 77
Self-citation
Metadata
- Authors
- Papadopoulos, D., & Mitsikostas, D.
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2010-06-10
- Volume
- 16
- Issue
- 7
- Pages
- 816-828
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2150720506
- Cited by
- 73
- References
- 9
- FWCI
- 0.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nocebo effects in multiple sclerosis trials: a meta-analysis. https://app.cochat.ai/papers/10.1177/1352458510370793
- The paper
- Papadopoulos, D., & Mitsikostas, D. (2010). Nocebo effects in multiple sclerosis trials: a meta-analysis. Multiple Sclerosis Journal. https://doi.org/10.1177/1352458510370793
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.